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A B S T R A C T
Introduction
Warm needle acupuncture (WA) is widely used the treatment in the East Asian countries. However, there is no crit-
ically appraised evidence of the potential benefits and harms. The purpose of this systematic review is to evaluate the
efficacy of WA for osteoarthritis (OA).
Methods and analysis
Electronic databases will be searched: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials
(CENTRAL) and AMED, 6 Korean medical databases (Korea Med, the Korean Traditional Knowledge Portal, OASIS,
DBPIA, the Research Information Service System and the Korean Studies Information Service System), 3 Chinese data-
bases (CNKI, VIP and Wanfang) and a Japanese database (CiNii Articles) will be searched from their inception. We will
be searched from their inception. Selection of the studies and data extraction and validation will be performed indepen-
dently by two reviewers. Randomised controlled trials (RCTs) and quasi-RCTs using WA for any type of OA will be
considered. The studies will independently undertake study selection, extraction of data and assessment of study quality
by two authors. Risk of bias will be assessed using the Cochrane risk of bias standards. All data synthesis and subgroup
analyses will be conducted using Review Manager Software.
Dissemination
Findings will be published in a peer-reviewed journals. This systematic review may inform the treatment of OA pa-
tients in clinical practice.
© 2016 Published by Elsevier Ltd.
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1. Introduction
1.1. Description of the condition
Osteoarthritis (OA) is a structural and functional failure of whole
joint [1] and damage to joint cartilage, deterioration of the bone be-
neath the joint, swelling of the joint with newly formed bone, and
mild inflammation of the synovial membrane [2]. Above all, OA is
often associated with significant disability and reduction in quality of
life [3]. This affects such as the knees, hips, fingers and lower spine.
Researchers have reported that the knee joint is affected especially
frequently, and the incidence of knee OA is increasing [4]. Unfor-
tunately, the available treatments for OA are not perfect. Therefore,
many studies, both pharmacological and non-pharmacological, focus
on reducing pain and limitations to patient’s daily functioning [5].
☆ Trial registration number: PROSPERO 2015: CRD42015024413
⁎ Corresponding author.
Email address: drmslee@gmail.com, mslee@kiom.re.kr (M.S. Lee)
1 These authors have contributed equally.
1.2. Description of the intervention
Acupuncture and moxibustion have been used as medical treat-
ments in East Asia, including China, Korea and Japan [6]. Moxi-
bustion have various techniques. There are two types of moxibus-
tion: be divided into direct moxibustion and indirect moxibustion.
When performing direct moxibustion, moxa sticks are burnt at acu-
points directly on the skin. In contrast, in indirect moxibustion, the
moxa cone does not touch the skin and is burnt while being insu-
lated from the skin by some substance [7]. Warm needle acupuncture
(WA) is the combination of acupuncture with moxibustion by stim-
ulating acupoints with a burning moxa (also called Ai Ye) stick on
the handle of the acupuncture needle [8]. The use of WA was first
documented in Shang Han Za Bing Lun (“Discussion of Cold-Induced
Disorders”), a classical Chinese medical book by Zhongjing Zhang
(Eastern Han dynasty, 25–220 C.E.) [9]. WA is often used to treat
painful conditions such as arthritis, especially rheumatoid arthritis and
OA [10,11] as well as musculoskeletal pain conditions [12,13]. WA
treatment is transmitted to the acupoint by radiation, moreover, by
direction conduction through the shaft of the needle, thereby stimu
http://dx.doi.org/10.1016/j.eujim.2016.07.030
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lating deep tissue within the acupoint and warming the acupoint on the
surface [14].
1.3. How the intervention might work
WA for OA is widely used for treatment and prevention [15,16].
Studies on the treatment of WA on OA have also shown a greater pain
relief compared to manual acupuncture [17]. Furthermore, WA has re-
duced joint fluid and abnormally high serum levels of interleukin-1
beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), two inflamma-
tory factors in patients with knee OA [18].
1.4. Why it is important to do this review
Many studies have been reported treatment using WA treatment for
OA in clinical practice [19,20]. One recent review assessed the effi-
cacy of WA for OA but the most of included studies suffered from
high risk of bias [21]. The previous review focused on the WA treat-
ment for knee OA and searched Chinses databases only. Furthermore,
the review is outdated. Therefore, the aim of this systematic review
was to update, complete and critically evaluate the evidence from ran-
domized clinical trials (RCTs) of WA for OA.
2. Methods
2.1. Study registration
This protocol review has been registered on PROSPERO 2015
(registration number CRD42015024413) [22].
2.2. Criteria for considering studies for this review
2.2.1. Types of studies
This systematic review will only include RCTs and quasi-RCTs.
Observational, cohort, case reports, case series, non-RCT, animal and
experimental studies will be excluded. No language restrictions will
be imposed.
2.2.2. Types of participants
Patients suffering from OA will be included regardless of joint lo-
cation (e.g., chronic condition of the neck, near the ends of the fingers,
at the base of the thumb, back, hip, and knee). We will also include
patients with both sexes and any age. Included patients will have been
diagnosed with OA according to the American College of Rheumatol-
ogy (ACR) criteria [23–25], the equivalent European League Against
Rheumatism (EULAR) criteria [26–28], or the Clinical Guideline of
New Drugs for Traditional Chinese Medicine [29]. Studies will be
excluded if they include patients with rheumatoid arthritis, ankylos-
ing arthritis, joint tuberculosis, purulent arthritis, allergic arthritis,
Kashin-Beck disease or Podagra.
2.2.3. Types of interventions and controls
Studies that evaluate WA as the sole intervention will be included.
Warm needle will be defined as moxa being attached to the nee-
dle once it is inserted. Traditionally, traditional medicine practition-
ers usually attach burning moxa to the handle of the AT needle to im-
prove the effectiveness of the therapy. Electro-warmed needles and
infrared radiation will be excluded. The combined intervention in-
clude western medicine or rehabilitation or physiotherapy, but ex-
clude alternative therapy such as herbal medicine, chuna, acupunc-
ture. A combined intervention will include western medicine or reha-
bilitation or physiotherapy, but will exclude any that combines other
alternative therapies such as herbal medicine, Tuina, or other types of
acupuncture.
2.2.4. Type of outcome measures
• Primary outcomes
1) Treatment efficacy: the number of patients whose OA symptoms
improved and treatment effectiveness.
2) Pain: associated scale measured on the visual analogue scale
(VAS) [30], Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) of pain [31], a numerical rating scale (NRS),
Verbal Rating Scale (VRS), the Faces Pain Scale-Revised (FPS-R),
etc.
3) Function of joint: measured by recognized scales including West-
ern Ontario and MacMaster universities arthritis index (WOMAC),
Lequesne score, etc.
• Secondary outcomes
1) Quality of life (QoL): measured using a validated questionnaire,
such as the short-form (36-item) health survey (SF-36) [32] or an-
other validated scale. 2. Adverse events
2.3. Search method for identifying the studies
2.3.1. Electronic searches
Electronic databases searched from their inception and will include
MEDLINE, EMBASE, the Cochrane Central Register of Controlled
Trials (CENTRAL) and AMED, 6 Korean databases (Korea Med, the
Korean Traditional Knowledge Portal, OASIS, DBPIA, the Research
Information Service System and the Korean Studies Information Ser-
vice System), 3 Chinese Databases (CNKI, VIP and Wanfang), and
the Japanese database (CiNii Articles). The search strategy will in-
clude warm needing acupuncture in English, Chinese and Korean.
2.3.2. Searches of other resources
The authors will scan the reference lists and retrieve additional
studies. In addition, authors will search the WHO International Clin-
ical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/
) and Google Scholar (http://scholar.google.co.kr/). Dissertations of
degree will be included. The ClinicalTrials.gov registry (http://
clinicaltrials.gov/) will be searched for any unpublished trials.
2.3.3. Search strategy
The strategy for searching MEDLINE is described in Appendix A.
The strategy for searching CNKI is described in Appendix B. Similar
search strategies will be applied to other databases.
2.4. Data collection, extraction and assessment
2.4.1. Selection of studies
Two reviewers (JHJ and TYC) will independently screen the ti-
tles and abstracts for searched studies, and perform study selection
and record their decisions according to predefined criteria. Another
reviewers (MSL) will resolve disagreements of section study. Study
selection will be documented and summarised in Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA) flow di-
agram [33].
2.4.2. Data extraction
Two reviewers (JHJ and TYC) will read studies and indepen-
dently extract the data using a standard data extraction form. The
form will be comprised of type of OA, participants, intervention
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group treatment, control group treatment, outcome and result. Dis-
agreements of section study will be resolved by another reviewers
(MSL). We will use Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) software to judge the quality of
evidence for data from Cochrane Systematic Reviews to create a Sum-
mary of Findings table [34]. Additionally, the details of the treatment
regimens will be summarised in a table. When reported data are insuf-
ficient or unclear, an author will contact the first author or correspond-
ing authors by e-mail or telephone to request missing or clarification
data.
2.4.3. Accessement of risk of bias
To assess the quality of included studies according to the criteria
described in the Cochrane Handbook for Systematic Reviews of In-
tervention [35]. The following items will be assessed: 1) random se-
quence generation; 2) allocation concealment; 3) blinding of partici-
pants and personnel; 4) blinding of outcome assessment; 5) complete-
ness of outcome data; 6) completeness of reporting; 7) other sources
of bias. Each trial will be categorized as having a low (L), unclear (U),
or high (H) risk of bias. If necessary, we will contact the authors of as-
sessed trials for clarification. We will resolve any differences in opin-
ion through discussion or consultation with all of the authors.
2.4.4. Data synthesis
All statistical analyses will be performed using the Review Man-
ager (Cochrane Collaboration Software, RevMan) version 5.3. For di-
chotomous data, we will present the treatment effects and use the risk
ratios (RR) with 95% confidence intervals (CIs). For the continuous
data, we will use the mean differences (MD) with 95% CIs. If out-
come variables are measured on different scales, we will use a stan-
dard mean differences (SMD) analysis with 95% CIs.
2.4.5. Unit of analysis issues
The systematic review will include data from parallel-group stud-
ies for the meta-analysis. For cross-over trials, the first treatment pe-
riod of data will be analyzed. In that case if there is more than one
control group, each group will constitute a separate unit of analy-
sis. If there are multiple treatment time observations, the data will be
analysed as either short term (within 30days) or long term (over 30-
days). In addition, analysis will be divided into various types of OA.
2.4.6. Assessment of heterogeneity
We will use fix model if there is no evidence of heterogeneity; if
not we will apply random effect model. If a meta-analysis is possible,
we will use the I2 statistic for quantifying inconsistencies across the in-
cluded studies. A result 50% cut off point would represent substantial
heterogeneity. If heterogeneity is observed, we will conduct subgroup
analyses [36].
2.4.7. Subgroup analysis and the investigation of heterogeneity
If studies and data are sufficient, subgroup analyses will be con-
ducted according to:
1) Type of OA (e.g, knees, hip, back or fingers)
2) Type of control intervention (e.g, western medicine, no treatment
or usual care)
2.4.8. Sensitivity analysis
We will use sensitivity analyses to investigate suspected funnel
plot asymmetry. Sensitivity analysis will be conducted according to
the following criteria:
1.) Methodological qualities (sequence generation, allocation con-
cealment, or blinding in the assessment of outcomes and symptom
severity)
2.) Sample size (more or less than 40 participants in each group)
In the analysis, we will exclude high risk of bias studies and com-
pare the results with those using the worst-case scenario to combine
studies. Then we will have a discussion to decide whether the high risk
of bias studies should be excluded on the bias of sample size, strength
of evidence and influence on pooled effect size.
2.4.9. Assessment of reporting biases
If more than 10 studies are available, we will conduct funnel plot
for publication bias and small study effects using Egger’s method.
Funnel plot asymmetry is certainly not same as publication bias. We
will attempt to distinguish the possible reasons for the asymmetry,
therefore, included poor methodological quality and true heterogene-
ity of studies [37].
3. Discussion
This protocol for a systematic review will provide a detailed sum-
mary of the current state of evidence regarding the effectiveness of the
WA in treating the symptoms of patients with OA. The review will be
useful to patients and healthcare providers in determining the appro-
priate role of WA in the treatment of OA.
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Appendix A. MEDLINE search strategy(PubMed)
#1. exp osteoarthritis/
#2. osteoarthr*.tw
#3. (degenerative adj2 arthritis).mp.
#4. arthrosis.mp.
#5. or/#1-#4
#6. exp acupuncture therapy/
#7. warm needle thechinique.mp.
#8. warm needle acupuncture.mp
#9. warm needle moxibustion.mp
#10. warm-needling. mp
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#11. wen zhen. mp
#12. warm$ acupuncture. mp
#13. or/#6-#12
#14. exp Randomized Controlled Trials as Topic/
#15. exp Clinical Trials as Topic/
#16. exp controlled clinical trials as topic/
#17. (randomized controlled trial* or controlled clinical trial* or
randomized* or randomly* or placebo or clinical trial* or controlled
trial*).mp.
#18. or/#14 − #17
#19. #5 and #13and #18
Appendix B. CNKI search stratege
#1.
#2.
#3. warm acupuncture
#4. warm needle acupuncture
#5. warming needle moxibustion
#6./or #1-5
#7.
#8. osteoarthritis OR osteoarthrosis OR ostearthritis OR Degen-
erative Osteoarthritis OR Knee osteoarthritis OR Hip Osteoarthritis
OR spine osteoarthritis OR Lumbar Spine Osteoarthritis OR Primary
Hypertrophic Osteoarthropathy OR Atlantoxial Osteoarthritis OR se-
nior osteoarthritis OR anteromedial osteoarthritis OR advanced os-
teoarthritis OR hand osteoarthritis
#9. OA OR KOA
#10. or/#7-9
#11.
#12.
#13. Randomized trials
#14. or/#11-13
#15. #6 and #10 and #14
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